Skip to content

Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus

Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus - the Patients' Perspective: a Randomized Controlled Trial Assessing Procedural Acceptability and Safety (RATE Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05051475
Acronym
RATE
Enrollment
62
Registered
2021-09-21
Start date
2021-12-01
Completion date
2025-05-05
Last updated
2025-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Barrett Esophagus, Esophageal Adenocarcinoma, Reflux Disease

Brief summary

This study compares patients' acceptability and safety of two established endoscopic methods for treating dysplastic Barrett's esophagus: radiofrequency ablation versus hybrid argon plasma coagulation.

Detailed description

Both endoscopic radiofrequency ablation (RFA) and argon plasma coagulation (APC) are established treatment modalities for dysplastic Barrett's esophagus. Recently, a modification of the APC method has emerged, which involves a submucosal injection of saline preceding the thermal ablation (hybrid-APC; h-APC). This allows to increase the procedure's safety and presumably reduces the patients' post-procedural discomfort. Although both RFA and h-APC are characterized by high effectiveness in eradicating Barrett's segments, limited data compares the patient-related aspects of the procedures. To fill this knowledge gap, we set out a single-center randomized-controlled trial to compare procedural acceptability, safety, and impact on the quality of life, of the two methods.

Interventions

Endoscopic ablation technique for Barrett's epithelium

PROCEDUREEndoscopic hybrid argon plasma coagulation

Endoscopic ablation technique for Barrett's epithelium

Sponsors

Maria Sklodowska-Curie National Research Institute of Oncology
CollaboratorOTHER
Centre of Postgraduate Medical Education
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Male or female subjects over 18 years * Histologically and endoscopically proven Barrett's esophagus requiring ablation therapy according to the current guidelines * General health status sufficient to perform an endoscopic procedure (ASA I-III)

Exclusion criteria

* Primary or secondary coagulopathy, with INR\>1.5 and/or platelet count of \<75,000. * Anticoagulation therapy (e.g. warfarin) for high-risk condition and unable to withhold the medication temporarily * Recent myocardial infraction or other significant cardiovascular event within 6 months prior to recruitment * Patients under long-term care and/or within nursing facilities (e.g. psychosocial disorders, mental retardation) * Any history of esophageal resection surgery * Esophageal varices

Design outcomes

Primary

MeasureTime frameDescription
Level of post-procedural painMeasured at any time point before given anesthesia for the procedure and immidietly after the procedure.Change in chest pain evaluated by the numeric analog scale (NAS) from score 0 (no pain) to 10 (worst possible pain) before the procedure and immidietly after (30-60 minutes) the procedure.
Level of post-procedural pain at day 7 after treatmentMeasured at day 7 after the procedurePost-procedural chest pain evaluated by the numeric analog scale (NAS) from score 0 (no pain) to 10 (worst possible pain)
Level of late post-procedural pain (at day 30 after treatment)Measured at day 30 after the procedurePost-procedural chest pain evaluated by the numeric analog scale (NAS) from score 0 (no pain) to 10 (worst possible pain)

Secondary

MeasureTime frameDescription
Level of post-procedural dysphagiaMeasured before the procedure, immidietly after (30-60mins), and at day 7, and day 30 after the procedure.Evaluated by the Mellow-Pinkas scoring from 0 (able to eat normal diet / no dysphagia) to 4 (unable to swallow anything / total dysphagia)
Level of post-procedural quality of lifeMeasured before the procedure, immidietly after (30-60mins), and at day 7, and day 30 after the procedure.Evaluated by the QLQ-OES18 questionnaire specific for esophageal symptoms, and consists of a symptom scale only. The QLQ-OES18 includes 18 questions: 6 single item subscales relating to saliva swallowing, choking, dry mouth, taste, coughing, and talking. It also includes 12 items grouped into 4 subscales: dysphagia (3 items), eating (4 items), reflux (2 items), and pain (3 items).
The rate of complicationsMeasured during the prcoedure, immidietly after the procedure and at day 7 and day 30 after the procedure during follow-upIntra-procedural complications, such as bleeding, perforation, post-procedural complications, e.g. chest-pain, esophageal stricture will be monitored during the hospital stay and follow-up at day 7 and day 30 after the procedure (phone call).

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026